BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the target of a large drop in short interest in November. As of November 15th, there was short interest totalling 1,350,000 shares, a drop of 29.7% from the October 31st total of 1,920,000 shares. Based on an average daily volume of 5,610,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 19.6% of the shares of the stock are sold short.

BioVie Trading Up 3.3 %

BIVI traded up $0.09 during trading on Friday, reaching $2.80. The company’s stock had a trading volume of 1,098,797 shares, compared to its average volume of 2,434,363. The firm has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $1.64. BioVie has a 1 year low of $1.04 and a 1 year high of $33.10.

BioVie (NASDAQ:BIVI) last released its earnings results on Monday, September 30th. The company reported ($6.60) earnings per share for the quarter.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.